MeiraGTx Says FDA Grants Rare Pediatric Disease Designation to Eye Disorder Drug

MT Newswires Live
22 Jan

MeiraGTx (MGTX) said Wednesday that the US Food and Drug Administration has granted its AAV8-RK-RetGC program rare pediatric disease designation for treating Leber congenital amaurosis caused by GUCY2D mutations (LCA1).

The company said it has received this fourth rare pediatric disease designation in the past three months, following similar designations for treatments targeting LCA4 retinal dystrophy, Bardet-Biedl syndrome, and RDH12-associated retinal dystrophy.

The designation is given to drugs for rare diseases affecting fewer than 200,000 patients, primarily those under 18. If a company gains approval for a treatment for a rare pediatric disease, it may receive a voucher for priority review of a future application, the company added.

Price: 6.13, Change: -0.28, Percent Change: -4.37

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10